Case Study: Osteosarcoma and Limb Salvage Surgery
Published on in CHOP News
Read this case study about a patient who received treatment for osteosarcoma and underwent limb salvage surgery at Children’s Hospital of Philadelphia.
Published on in CHOP News
Read this case study about a patient who received treatment for osteosarcoma and underwent limb salvage surgery at Children’s Hospital of Philadelphia.
Published on in CHOP News
The CHOP-engineered therapy overcomes common drug resistance and has potential to elicit fewer toxicities than most cancer treatments.
Published on in Orthopaedics Update, Oncology Update
This case study highlights a multimodal approach to surgical management of osteosarcomas in young children, maximizing control while providing a functional limb that will grow with the child.
Published on in Oncology Update
Patrick J. Grohar, MD, PhD, focuses on developing therapies for a cancer that’s rare in adults but relatively common in the pediatric population.
Published on in CHOP News
An unrelenting, deep bone pain that woke him up from sleep is what led to Jake’s diagnosis just last March of Ewing sarcoma, one of the most common bone tumors in children and adolescents.
Published on in CHOP News
CHOP recipient, physician-scientist Dr. Yael Mossé, is innovating targeted, less toxic therapies for cancer affecting mostly infants and young children.
Published on in CHOP News
CHOP physician-scientists applaud a new drug for childhood cancer that targets a key genetic driver of cancer rather than a specific type of tumor.
Published on in Children's Doctor
The CHAMP Lab at CHOP has created numerous 3D models to aide in the surgical care of patients with complex congenital anomalies and tumors.
Published on in CHOP News
A CHOP research leader received an award from the University City Science Center to help develop a new T-cell based treatment for a childhood cancer.
Published on in Cancer Connections
Researchers at CHOP are working to discover the fundamental mechanisms that subvert normal neural development and orchestrate neuroblastoma tumorigenesis, and then to translate this knowledge into more effective and less toxic therapies.